Segment: I Love My Blog!

Klik baner .

I love my blog because my blog ibarat diari harian aku . Kat blog nhe aku dapat share pendapat , maklumat dan pengetahuan aku dengan semua blogger . Selain itu , blog aku nhe selalu menjadi mangsa tempat aku meluah segala isi hati aku . Aku jugak sanggup mencari pelbagai tutorial untuk diaplikasi dalam blog aku nhe . Aku lebih suka blog aku simple dan tak banyak hiasan bagai . Dengan adanya blog nhe , aku dapat kenalan baru dan secara automatik followers jugak akan bertambah . Bagi aku followers adalah nyawa blog aku . Begitu jugak dengan readers . Tanpa followers dan readers blog aku tak akan hidup sampai sekarang . =p . Aku sedar yang blog aku nhe tak cun macam blog - blog yang lain . Tapi , aku akan tingkatkan usaha dalam berblogging dari semasa ke semasa . Dari hari ke hari ada saja perubahan yang aku buat kat blog aku nhe supaya nampak kemas dan simple . Thanks =) .

Jom join ^.^


  1. Rieya Ramlee Tor9/7/12 10:27 PM


    Thanks for joining my segment. This segment will be judge by me and others too.

  2. The Supreme Courtroom of Canada has opened the door to enabling international multinational firms to dodge their Canadian tax liabilities by siding with British drugmaker GlaxoSmithKline in its 20-year tax struggle with all the federal government.

    The significant courtroom endorsed an appeals court ruling about "transfer pricing," which allows for [url=]fioricet info[/url] multinationals to charge their subsidiaries great costs for ingredient charges so that they can cut down Canadian gains.

    The Department of Nationwide Income had challenged Glaxo Canada's usage of a licence arrangement that authorized it to pay Glaxo Swiss subsidiary Adechsa among $1,512 and $1,651 for each kilogram for that obtain of ranitidine, the active ingredient inside anti-ulcer drug Zantac.

    Glaxo also compensated mother or father organization Glaxo Team a 6 per cent royalty on net sales and profits of Zantac.

    The value of ranitidine exceeded the $194 to $304 for every kilogram billed to Canadian generic pharmaceutical firms Apotex Inc. and Novopharm Inc. by arm's-length suppliers.

    The government productively argued in Tax Courtroom that making use of the "reasonable" prices to Glaxo Canada would've increased the subsidiary's net cash for 1990 to 1993 by $51 million. Even so the Federal Courtroom of Appeal in July 2010 overturned the Tax Court's selection and rejected the department's argument that reasonable marketplace benefit paid by generics was the suitable evaluate. It sent the calculation again for the Tax Courtroom for any redetermination.

    Creating to the Supreme Courtroom, Justice Marshall Rothstein said inside a ruling introduced Thursday the Tax Court "erred in refusing to consider account of your licence agreement."

    "The generic comparators never reflect the economic system and internet marketing business fact of Glaxo Canada and, at the least not having adjustment, do no indicate the cost that would be cheap while in the circumstance, experienced Glaxo Canada and Adechsa been dealing at arm's length."

    Queen's College tax regulation qualified Artwork Cockfield explained the ruling is mostly a gain for Glaxo and [url=]fioricet[/url] could prompt other people to adopt advanced cross-border tax structures to shift revenue to low-tax jurisdictions.

    "There's huge flows planning back and forth and suppliers have an incentive to sport the strategy by shifting earnings typically to your lowest-tax country," he said. "It's unfavorable for Canada mainly because it supports aggressive worldwide tax arranging that sends revenues outside the house from the nation."

    Canada's cheaper company tax charge compared to the U.S. could, still, insulate it from these income shifts involving firms with operations on both sides of your border, Cockfield extra.


Jom komen banyak - banyak kat sini !